dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Grau Vorster, Marta |
dc.contributor.author | Lopez Montañes, Maria |
dc.contributor.author | Canto Puig, Ester |
dc.contributor.author | Vives Armengol, Joaquim |
dc.contributor.author | Oliver-Vila, Irene |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Rudilla Salvador, Francesc |
dc.date.accessioned | 2021-09-08T07:38:53Z |
dc.date.available | 2021-09-08T07:38:53Z |
dc.date.issued | 2020-02-25 |
dc.identifier.citation | Grau-Vorster M, López-Montañés M, Cantó E, Vives J, Oliver-Vila I, Barba P, et al. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Front Immunol. 2020 Feb 25;11:271. |
dc.identifier.issn | 1664-3224 |
dc.identifier.uri | https://hdl.handle.net/11351/6278 |
dc.description | Immunoteràpia adoptiva; Citotoxicitat; Limfòcits T específics del virus (VST) |
dc.description.sponsorship | Work in our laboratory was supported by the Spanish Cell Therapy Network (TerCel, file No. RD16/0011/0028), and carried out as part of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Catalan government) under the Catalonian ERDF operational program (European Regional Development Fund) 2014-2020. Our laboratory was certified by the Catalan government as a Consolidated Research Group (ref. 2017SGR719). |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Immunology;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Infeccions per citomegalovirus |
dc.subject | Cèl·lules T |
dc.subject | Immunoteràpia |
dc.subject.mesh | Immunotherapy, Adoptive |
dc.subject.mesh | T-Lymphocytes, Cytotoxic |
dc.subject.mesh | Cytomegalovirus Infections |
dc.title | Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fimmu.2020.00271 |
dc.subject.decs | infecciones por Citomegalovirus |
dc.subject.decs | inmunoterapia adoptiva |
dc.subject.decs | linfocitos T citotóxicos |
dc.relation.publishversion | https://doi.org/10.3389/fimmu.2020.00271 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Grau-Vorster M, López-Montañés M, Cantó E, Rudilla F] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vives J] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. Grup de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup d’Enginyeria tissular musculoesquelètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Oliver-Vila I] Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 32161589 |
dc.identifier.wos | 000524779300001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0011%2F0028 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR719 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |